Telmisartan Improves Insulin Resistance of Skeletal Muscle Through Peroxisome Proliferator–Activated Receptor-δ Activation
The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-spec...
Saved in:
| Published in | Diabetes (New York, N.Y.) Vol. 62; no. 3; pp. 762 - 774 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Alexandria, VA
American Diabetes Association
01.03.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0012-1797 1939-327X 1939-327X |
| DOI | 10.2337/db12-0570 |
Cover
| Abstract | The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-specific peroxisome proliferator–activated receptor (PPAR) δ knockout (MCK-PPARδ−/−) mice. Telmisartan increased PPARδ expression and activated PPARδ transcriptional activity in cultured C2C12 myotubes. In palmitate-induced insulin-resistant C2C12 myotubes, telmisartan enhanced insulin-stimulated Akt and Akt substrate of 160 kDa (AS160) phosphorylation as well as Glut4 translocation to the plasma membrane. These effects were inhibited by antagonizing PPARδ or phosphatidylinositol-3 kinase, but not by PPARγ and PPARα inhibition. Palmitate reducing the insulin-stimulated glucose uptake in C2C12 myotubes could be restored by telmisartan. In vivo experiments showed that telmisartan treatment reversed high-fat diet–induced insulin resistance and glucose intolerance in wild-type mice but not in MCK-PPARδ−/− mice. The protein levels of PPARδ, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice. These effects were absent in MCK-PPARδ−/− mice. These findings implicate PPARδ as a potential therapeutic target in the treatment of hypertensive subjects with insulin resistance. |
|---|---|
| AbstractList | The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-specific peroxisome proliferator–activated receptor (PPAR) δ knockout (MCK-PPARδ−/−) mice. Telmisartan increased PPARδ expression and activated PPARδ transcriptional activity in cultured C2C12 myotubes. In palmitate-induced insulin-resistant C2C12 myotubes, telmisartan enhanced insulin-stimulated Akt and Akt substrate of 160 kDa (AS160) phosphorylation as well as Glut4 translocation to the plasma membrane. These effects were inhibited by antagonizing PPARδ or phosphatidylinositol-3 kinase, but not by PPARγ and PPARα inhibition. Palmitate reducing the insulin-stimulated glucose uptake in C2C12 myotubes could be restored by telmisartan. In vivo experiments showed that telmisartan treatment reversed high-fat diet–induced insulin resistance and glucose intolerance in wild-type mice but not in MCK-PPARδ−/− mice. The protein levels of PPARδ, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice. These effects were absent in MCK-PPARδ−/− mice. These findings implicate PPARδ as a potential therapeutic target in the treatment of hypertensive subjects with insulin resistance. The mechanisms of the improvement of glucose homeostasis through anglotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-specific peroxisome proliferator-activated receptor (PPAR) δ knockout (MCK-[PPARδ.sup.- /-] mice. Telmisartan increased PPARδ expression and activated PPARδ transcriptional activity in cultured C2C12 myotubes. In palmitate-induced insulin-resistant C2C12 myotubes, telmisartan enhanced insulin-stimulated Akt and Akt substrate of 160 kDa (AS160) phosphorylation as well as Glut4 translocation to the plasma membrane. These effects were inhibited by antagonizing PPARδ or phosphatidylinositol-3 kinase, but not by PPARγ and PPARα inhibition. Palmitate reducing the insulin- stimulated glucose uptake in C2C12 myotubes could be restored by telmisartan. In vivo experiments showed that telmisartan treatment reversed high-fat diet-induced insulin resistance and glucose intolerance in wild-type mice but not in MCK-PPAR[δ.sup.-/-] mice. The protein levels of PPARδ, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice. These effects were absent in MCK-PPAR[δ.sup.-/-] mice. These findings implicate PPARδ as a potential therapeutic target in the treatment of hypertensive subjects with insulin resistance. The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-specific peroxisome proliferator-activated receptor (PPAR) δ knockout (MCK-PPARδ(-/-)) mice. Telmisartan increased PPARδ expression and activated PPARδ transcriptional activity in cultured C2C12 myotubes. In palmitate-induced insulin-resistant C2C12 myotubes, telmisartan enhanced insulin-stimulated Akt and Akt substrate of 160 kDa (AS160) phosphorylation as well as Glut4 translocation to the plasma membrane. These effects were inhibited by antagonizing PPARδ or phosphatidylinositol-3 kinase, but not by PPARγ and PPARα inhibition. Palmitate reducing the insulin-stimulated glucose uptake in C2C12 myotubes could be restored by telmisartan. In vivo experiments showed that telmisartan treatment reversed high-fat diet-induced insulin resistance and glucose intolerance in wild-type mice but not in MCK-PPARδ(-/-) mice. The protein levels of PPARδ, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice. These effects were absent in MCK-PPARδ(-/-) mice. These findings implicate PPARδ as a potential therapeutic target in the treatment of hypertensive subjects with insulin resistance. The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-specific peroxisome proliferator-activated receptor (PPAR) δ knockout (MCK-PPARδ(-/-)) mice. Telmisartan increased PPARδ expression and activated PPARδ transcriptional activity in cultured C2C12 myotubes. In palmitate-induced insulin-resistant C2C12 myotubes, telmisartan enhanced insulin-stimulated Akt and Akt substrate of 160 kDa (AS160) phosphorylation as well as Glut4 translocation to the plasma membrane. These effects were inhibited by antagonizing PPARδ or phosphatidylinositol-3 kinase, but not by PPARγ and PPARα inhibition. Palmitate reducing the insulin-stimulated glucose uptake in C2C12 myotubes could be restored by telmisartan. In vivo experiments showed that telmisartan treatment reversed high-fat diet-induced insulin resistance and glucose intolerance in wild-type mice but not in MCK-PPARδ(-/-) mice. The protein levels of PPARδ, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice. These effects were absent in MCK-PPARδ(-/-) mice. These findings implicate PPARδ as a potential therapeutic target in the treatment of hypertensive subjects with insulin resistance.The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and muscle-specific peroxisome proliferator-activated receptor (PPAR) δ knockout (MCK-PPARδ(-/-)) mice. Telmisartan increased PPARδ expression and activated PPARδ transcriptional activity in cultured C2C12 myotubes. In palmitate-induced insulin-resistant C2C12 myotubes, telmisartan enhanced insulin-stimulated Akt and Akt substrate of 160 kDa (AS160) phosphorylation as well as Glut4 translocation to the plasma membrane. These effects were inhibited by antagonizing PPARδ or phosphatidylinositol-3 kinase, but not by PPARγ and PPARα inhibition. Palmitate reducing the insulin-stimulated glucose uptake in C2C12 myotubes could be restored by telmisartan. In vivo experiments showed that telmisartan treatment reversed high-fat diet-induced insulin resistance and glucose intolerance in wild-type mice but not in MCK-PPARδ(-/-) mice. The protein levels of PPARδ, phospho-Akt, phospho-AS160, and Glut4 translocation to the plasma membrane in the skeletal muscle on insulin stimulation were reduced by high-fat diet and were restored by telmisartan administration in wild-type mice. These effects were absent in MCK-PPARδ(-/-) mice. These findings implicate PPARδ as a potential therapeutic target in the treatment of hypertensive subjects with insulin resistance. |
| Audience | Professional |
| Author | He, Hongbo Li, Li Zhao, Yu Feng, Xiaoli Pu, Yunfei Luo, Zhidan Yu, Hao Chen, Jian Liu, Daoyan Zhu, Zhiming Zhong, Jian Wang, Peijian |
| Author_xml | – sequence: 1 givenname: Li surname: Li fullname: Li, Li organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 2 givenname: Zhidan surname: Luo fullname: Luo, Zhidan organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 3 givenname: Hao surname: Yu fullname: Yu, Hao organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 4 givenname: Xiaoli surname: Feng fullname: Feng, Xiaoli organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 5 givenname: Peijian surname: Wang fullname: Wang, Peijian organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 6 givenname: Jian surname: Chen fullname: Chen, Jian organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 7 givenname: Yunfei surname: Pu fullname: Pu, Yunfei organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 8 givenname: Yu surname: Zhao fullname: Zhao, Yu organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 9 givenname: Hongbo surname: He fullname: He, Hongbo organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 10 givenname: Jian surname: Zhong fullname: Zhong, Jian organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 11 givenname: Daoyan surname: Liu fullname: Liu, Daoyan organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China – sequence: 12 givenname: Zhiming surname: Zhu fullname: Zhu, Zhiming organization: Center for Hypertension and Metabolic Diseases, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27129928$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23238297$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1klFuEzEQhi1URNPCAxdAKyEkirTt2t7Euy9IUdWWSEFUECTeLMc7TgxeO7W9oX1A4g5chXNwCE6C0wRKUNA8WJr55rf9zxygPessIPQYF8eEUnbSTDHJiz4r7qEermmdU8I-7KFeUaQ8ZjXbRwchfCyKYpDiAdonlNCK1KyHvkzAtDoIH4XNRu3CuyWEbGRDZ7TN3kLQIVUkZE5l7z6BgShM9roL0kA2mXvXzebZJXh3rYNrIbv0zmgFXkTnf379NpRRL0WEJilJWKRk_uN7tslqZx-i-0qYAI825yF6f342OX2Vj99cjE6H41yWrIw5MMYaoYiiDZUgJStqLGhZDhQlCqZlKapBXZUM12xQVqovK6hUo6YNqH4hpyU9RC_Wup1diJvPwhi-8LoV_objgq885CsP-crDBL9cw4tu2kIjwUYv7hqc0Hy7YvWcz9yS036FCamTwPONgHdXHYTIk8MSjBEWXBc4pphgRtjtXU_X6EwY4NoqlxTlCudDSjCl_fSnROU7qBnYZLRJq6B0Sm_xxzv4FA20Wu5sONpqSEyE6zgTXQi8uhhvs0_-tuePL793KgHPNoAIUhjl0_7ocMcxTOqaVIk7WXPSuxA8KC51vF2L9Fptdk7m6J-O_0_xF5Zn-xg |
| CODEN | DIAEAZ |
| CitedBy_id | crossref_primary_10_1016_j_dsx_2016_08_009 crossref_primary_10_1007_s11325_014_1081_y crossref_primary_10_1038_hr_2013_157 crossref_primary_10_1001_jama_2022_16797 crossref_primary_10_1016_j_jphs_2018_11_007 crossref_primary_10_1113_expphysiol_2014_081596 crossref_primary_10_15829_1728_8800_2020_1_2453 crossref_primary_10_1016_j_biopha_2024_116169 crossref_primary_10_1016_j_abb_2016_05_020 crossref_primary_10_1016_j_jcte_2015_08_001 crossref_primary_10_3389_fphar_2023_1228525 crossref_primary_10_1038_s41598_019_40322_1 crossref_primary_10_1155_2019_7809216 crossref_primary_10_7759_cureus_22301 crossref_primary_10_1038_s41598_017_14265_4 crossref_primary_10_1152_ajpendo_00391_2014 crossref_primary_10_1042_CS20160780 crossref_primary_10_1016_j_bbrc_2019_12_111 crossref_primary_10_1016_j_bbi_2017_04_023 crossref_primary_10_1161_JAHA_117_005812 crossref_primary_10_1186_s12933_016_0430_5 crossref_primary_10_1096_fj_202000300R crossref_primary_10_1155_2014_972761 crossref_primary_10_1155_2013_509502 crossref_primary_10_1093_ajh_hpu197 crossref_primary_10_1007_s00125_015_3814_2 crossref_primary_10_1016_j_cmet_2016_02_019 crossref_primary_10_1038_s42255_021_00520_6 crossref_primary_10_1185_03007995_2016_1171204 crossref_primary_10_12701_yujm_2019_00059 crossref_primary_10_15829_1728_8800_2020_1_106_117 crossref_primary_10_1002_jcb_27425 crossref_primary_10_1007_s10571_015_0327_y crossref_primary_10_1016_j_tem_2016_02_008 crossref_primary_10_3390_ijms24032345 crossref_primary_10_1016_j_bioorg_2025_108226 crossref_primary_10_1155_2016_2612743 crossref_primary_10_1016_j_pharmthera_2016_03_019 crossref_primary_10_4103_sjo_sjo_15_18 |
| Cites_doi | 10.1161/HYPERTENSIONAHA.109.138750 10.1177/009127000004001210 10.1124/pr.109.001560 10.1074/jbc.M702329200 10.1161/HYPERTENSIONAHA.109.145409 10.1038/nm1026 10.1016/j.cmet.2010.10.005 10.1038/nm993 10.1161/01.HYP.0000078490.59735.6E 10.1056/NEJMoa1001121 10.1161/01.HYP.0000123072.34629.57 10.1055/s-0030-1252069 10.1165/rcmb.2007-0426OC 10.2337/db12-0073 10.1161/HYPERTENSIONAHA.109.143958 10.1371/journal.pbio.0020294 10.1016/j.bbrc.2006.12.213 10.1093/cvr/cvq392 10.1161/01.RES.0000262653.84850.8b 10.1016/j.cmet.2008.04.002 10.1016/j.biocel.2005.08.007 10.1073/pnas.0308096101 10.1161/STROKEAHA.110.583948 10.1101/gad.178434.111 10.1073/pnas.0511253103 10.1007/s12325-011-0040-2 10.1016/j.cmet.2006.10.003 10.1016/j.cmet.2011.06.015 10.1038/nm1546 10.1096/fj.03-0269fje 10.1124/jpet.109.159806 10.2337/diabetes.47.4.507 10.1093/jmcb/mjs001 10.2337/diabetes.54.12.3442 10.1152/ajpendo.90908.2008 10.1210/en.2008-0502 10.1016/S1097-2765(00)80155-0 10.1016/j.jhep.2009.01.021 10.1016/j.cmet.2008.09.011 10.1038/nature08446 10.1038/nrm3351 10.2337/diabetes.54.4.1157 10.1152/ajpheart.00796.2011 10.1016/j.cellsig.2010.03.004 10.1161/01.HYP.0000225402.69580.1d 10.2337/db07-0839 |
| ContentType | Journal Article |
| Copyright | 2014 INIST-CNRS COPYRIGHT 2013 American Diabetes Association 2013 by the American Diabetes Association. 2013 |
| Copyright_xml | – notice: 2014 INIST-CNRS – notice: COPYRIGHT 2013 American Diabetes Association – notice: 2013 by the American Diabetes Association. 2013 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 8GL 7X8 5PM ADTOC UNPAY |
| DOI | 10.2337/db12-0570 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: High School MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1939-327X |
| EndPage | 774 |
| ExternalDocumentID | 10.2337/db12-0570 PMC3581229 A321335197 23238297 27129928 10_2337_db12_0570 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 7RV 7X7 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8GL 8R4 8R5 AAFWJ AAKAS AAQQT AAWTL AAYEP AAYXX ABOCM ABUWG ACGFO ACGOD ACPRK ADBBV ADGHP ADZCM AEGXH AENEX AERZD AFKRA AHMBA AIAGR AIZAD ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BBNVY BCR BCU BEC BENPR BES BHPHI BKEYQ BKNYI BLC BPHCQ BTFSW BVXVI CCPQU CITATION CS3 DIK DU5 DWQXO E3Z EBS EDB EJD EMOBN EX3 F5P FRP FYUFA GICCO GNUQQ GUQSH GX1 H13 HCIFZ HMCUK HZ~ IAG IAO IEA IHR INH INR IOF IPO ITC K-O K2M K9- KQ8 L7B LK8 M0R M1P M2O M2P M2Q M5~ M7P NAPCQ O5R O5S O9- OB3 OHH OK1 OVD P2P PCD PEA PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q2X RHI RPM S0X SJFOW SJN SV3 TDI TEORI TR2 UKHRP VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM .GJ 1CY 8F7 AAYJJ AAYOK AFFNX AI. ALIPV C1A H~9 IQODW J5H MVM N4W VH1 XOL YQJ ZGI ZXP CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC AFLOD UNPAY |
| ID | FETCH-LOGICAL-c474t-e777daf2f3d3cecc7091a3446f32feb44a869847197648f5c8e8fdfbdef50cb43 |
| IEDL.DBID | UNPAY |
| ISSN | 0012-1797 1939-327X |
| IngestDate | Sun Oct 26 03:49:53 EDT 2025 Tue Sep 30 16:46:43 EDT 2025 Wed Oct 01 13:56:18 EDT 2025 Mon Oct 20 21:50:53 EDT 2025 Thu Jun 12 23:46:09 EDT 2025 Mon Oct 20 16:48:40 EDT 2025 Thu Oct 16 15:01:07 EDT 2025 Mon Jul 21 05:40:17 EDT 2025 Wed Apr 02 07:26:44 EDT 2025 Thu Apr 24 23:11:50 EDT 2025 Wed Oct 01 03:44:51 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Endocrinopathy Target tissue resistance Diabetes mellitus Metabolic diseases Insulin resistance Striated muscle Peroxisome proliferator activated receptor |
| Language | English |
| License | CC BY 4.0 Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. cc-by-nc-nd |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-e777daf2f3d3cecc7091a3446f32feb44a869847197648f5c8e8fdfbdef50cb43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 L.L. and Z.L. contributed equally to this study. |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://diabetes.diabetesjournals.org/content/diabetes/62/3/762.full.pdf |
| PMID | 23238297 |
| PQID | 1312172770 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | unpaywall_primary_10_2337_db12_0570 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581229 proquest_miscellaneous_1312172770 gale_infotracmisc_A321335197 gale_infotracgeneralonefile_A321335197 gale_infotracacademiconefile_A321335197 gale_incontextgauss_8GL_A321335197 pubmed_primary_23238297 pascalfrancis_primary_27129928 crossref_citationtrail_10_2337_db12_0570 crossref_primary_10_2337_db12_0570 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-03-01 |
| PublicationDateYYYYMMDD | 2013-03-01 |
| PublicationDate_xml | – month: 03 year: 2013 text: 2013-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Alexandria, VA |
| PublicationPlace_xml | – name: Alexandria, VA – name: United States |
| PublicationTitle | Diabetes (New York, N.Y.) |
| PublicationTitleAlternate | Diabetes |
| PublicationYear | 2013 |
| Publisher | American Diabetes Association |
| Publisher_xml | – name: American Diabetes Association |
| References | Schuler (2022031210130799800_B14) 2006; 4 de Luis (2022031210130799800_B34) 2010; 25 Krämer (2022031210130799800_B47) 2005; 54 Pedchenko (2022031210130799800_B46) 2008; 39 Pang (2022031210130799800_B44) 2009; 50 Wang (2022031210130799800_B24) 2010; 118 He (2022031210130799800_B38) 2010; 55 Merlin (2022031210130799800_B23) 2010; 22 Alkhateeb (2022031210130799800_B29) 2009; 297 Washida (2022031210130799800_B36) 2010; 41 Schupp (2022031210130799800_B6) 2005; 54 Lee (2022031210130799800_B15) 2006; 103 McMurray (2022031210130799800_B3) 2010; 362 Araki (2022031210130799800_B37) 2006; 48 Gupta (2022031210130799800_B18) 2004; 10 Furuhashi (2022031210130799800_B5) 2003; 42 Tikellis (2022031210130799800_B39) 2006; 38 Luquet (2022031210130799800_B12) 2003; 17 Yan (2022031210130799800_B25) 2007; 354 Mori (2022031210130799800_B33) 2011; 28 Zhang (2022031210130799800_B20) 2007; 100 Leto (2022031210130799800_B30) 2012; 13 Wang (2022031210130799800_B16) 2004; 2 Spiegelman (2022031210130799800_B8) 1998; 47 Grimaldi (2022031210130799800_B9) 2010; 12 Benson (2022031210130799800_B7) 2004; 43 Brunham (2022031210130799800_B41) 2007; 13 Yip (2022031210130799800_B32) 2008; 8 Putnam (2022031210130799800_B2) 2012; 302 Krämer (2022031210130799800_B11) 2007; 282 Levskaya (2022031210130799800_B26) 2009; 461 Yuen (2022031210130799800_B40) 2011; 90 Chai (2022031210130799800_B4) 2010; 55 Harman (2022031210130799800_B17) 2004; 10 Gan (2022031210130799800_B13) 2011; 25 Tagami (2022031210130799800_B28) 2009; 150 Xie (2022031210130799800_B31) 2011; 14 Ma (2022031210130799800_B21) 2012; 4 Kang (2022031210130799800_B43) 2008; 7 Yamamoto (2022031210130799800_B27) 2009; 54 Brüning (2022031210130799800_B19) 1998; 2 McClung (2022031210130799800_B22) 2004; 101 Clemenz (2022031210130799800_B42) 2008; 57 Taylor (2022031210130799800_B1) 2012; 61 Jimenez (2022031210130799800_B45) 2010; 332 Ehrenborg (2022031210130799800_B10) 2009; 61 Smith (2022031210130799800_B35) 2000; 40 16717145 - Hypertension. 2006 Jul;48(1):51-7 16492734 - Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3444-9 19147680 - Endocrinology. 2009 Feb;150(2):862-70 21907143 - Cell Metab. 2011 Sep 7;14(3):378-89 17322896 - Nat Med. 2007 Mar;13(3):340-7 12796280 - Hypertension. 2003 Jul;42(1):76-81 17500064 - J Biol Chem. 2007 Jul 6;282(27):19313-20 21744143 - Adv Ther. 2011 Aug;28(8):698-706 20228403 - N Engl J Med. 2010 Apr 22;362(16):1477-90 21035761 - Cell Metab. 2010 Nov 3;12(5):509-20 22135324 - Genes Dev. 2011 Dec 15;25(24):2619-30 20176998 - Hypertension. 2010 Apr;55(4):869-79 14758356 - Nat Med. 2004 Mar;10(3):245-7 22442298 - Diabetes. 2012 Apr;61(4):778-9 19749742 - Nature. 2009 Oct 15;461(7266):997-1001 20595663 - Stroke. 2010 Aug;41(8):1798-806 16306360 - Diabetes. 2005 Dec;54(12):3442-52 18184928 - Diabetes. 2008 May;57(5):1405-13 22617471 - Nat Rev Mol Cell Biol. 2012 Jun;13(6):383-96 15184668 - Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8852-7 15328533 - PLoS Biol. 2004 Oct;2(10):e294 19996061 - Hypertension. 2010 Feb;55(2):523-30 14525942 - FASEB J. 2003 Dec;17(15):2299-301 21156825 - Cardiovasc Res. 2011 Apr 1;90(1):122-9 17347480 - Circ Res. 2007 Apr 13;100(7):1063-70 15793256 - Diabetes. 2005 Apr;54(4):1157-63 17223076 - Biochem Biophys Res Commun. 2007 Mar 9;354(2):427-33 15007034 - Hypertension. 2004 May;43(5):993-1002 19398227 - J Hepatol. 2009 Jun;50(6):1192-201 22227126 - Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1219-30 16198140 - Int J Biochem Cell Biol. 2006;38(5-6):737-51 20206685 - Cell Signal. 2010 Jul;22(7):1104-13 20429048 - Exp Clin Endocrinol Diabetes. 2010 Oct;118(9):657-61 20449538 - Nutr Hosp. 2010 Mar-Apr;25(2):275-9 9568680 - Diabetes. 1998 Apr;47(4):507-14 18566335 - Am J Respir Cell Mol Biol. 2008 Dec;39(6):689-96 19805479 - Pharmacol Rev. 2009 Sep;61(3):373-93 19822796 - Hypertension. 2009 Dec;54(6):1353-9 15048110 - Nat Med. 2004 May;10(5):481-3 22241835 - J Mol Cell Biol. 2012 Apr;4(2):88-96 11185637 - J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1380-90 18522830 - Cell Metab. 2008 Jun;7(6):485-95 19906781 - J Pharmacol Exp Ther. 2010 Feb;332(2):554-61 9844629 - Mol Cell. 1998 Nov;2(5):559-69 19724017 - Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1056-66 17084713 - Cell Metab. 2006 Nov;4(5):407-14 19046570 - Cell Metab. 2008 Nov;8(5):384-98 |
| References_xml | – volume: 54 start-page: 1353 year: 2009 ident: 2022031210130799800_B27 article-title: Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.109.138750 – volume: 40 start-page: 1380 year: 2000 ident: 2022031210130799800_B35 article-title: Dose response and safety of telmisartan in patients with mild to moderate hypertension publication-title: J Clin Pharmacol doi: 10.1177/009127000004001210 – volume: 61 start-page: 373 year: 2009 ident: 2022031210130799800_B10 article-title: Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta publication-title: Pharmacol Rev doi: 10.1124/pr.109.001560 – volume: 282 start-page: 19313 year: 2007 ident: 2022031210130799800_B11 article-title: Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle publication-title: J Biol Chem doi: 10.1074/jbc.M702329200 – volume: 55 start-page: 523 year: 2010 ident: 2022031210130799800_B4 article-title: Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.109.145409 – volume: 10 start-page: 481 year: 2004 ident: 2022031210130799800_B17 article-title: Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis publication-title: Nat Med doi: 10.1038/nm1026 – volume: 12 start-page: 509 year: 2010 ident: 2022031210130799800_B9 article-title: PER2 controls lipid metabolism by direct regulation of PPARγ publication-title: Cell Metab doi: 10.1016/j.cmet.2010.10.005 – volume: 10 start-page: 245 year: 2004 ident: 2022031210130799800_B18 article-title: Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth publication-title: Nat Med doi: 10.1038/nm993 – volume: 42 start-page: 76 year: 2003 ident: 2022031210130799800_B5 article-title: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension publication-title: Hypertension doi: 10.1161/01.HYP.0000078490.59735.6E – volume: 362 start-page: 1477 year: 2010 ident: 2022031210130799800_B3 article-title: Effect of valsartan on the incidence of diabetes and cardiovascular events publication-title: N Engl J Med doi: 10.1056/NEJMoa1001121 – volume: 43 start-page: 993 year: 2004 ident: 2022031210130799800_B7 article-title: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity publication-title: Hypertension doi: 10.1161/01.HYP.0000123072.34629.57 – volume: 118 start-page: 657 year: 2010 ident: 2022031210130799800_B24 article-title: Palmitate induced insulin resistance by PKCtheta-dependent activation of mTOR/S6K pathway in C2C12 myotubes publication-title: Exp Clin Endocrinol Diabetes doi: 10.1055/s-0030-1252069 – volume: 39 start-page: 689 year: 2008 ident: 2022031210130799800_B46 article-title: Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2007-0426OC – volume: 61 start-page: 778 year: 2012 ident: 2022031210130799800_B1 article-title: Insulin resistance and type 2 diabetes publication-title: Diabetes doi: 10.2337/db12-0073 – volume: 55 start-page: 869 year: 2010 ident: 2022031210130799800_B38 article-title: Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.109.143958 – volume: 2 start-page: e294 year: 2004 ident: 2022031210130799800_B16 article-title: Regulation of muscle fiber type and running endurance by PPARdelta publication-title: PLoS Biol doi: 10.1371/journal.pbio.0020294 – volume: 354 start-page: 427 year: 2007 ident: 2022031210130799800_B25 article-title: Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.12.213 – volume: 90 start-page: 122 year: 2011 ident: 2022031210130799800_B40 article-title: Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase publication-title: Cardiovasc Res doi: 10.1093/cvr/cvq392 – volume: 100 start-page: 1063 year: 2007 ident: 2022031210130799800_B20 article-title: Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity publication-title: Circ Res doi: 10.1161/01.RES.0000262653.84850.8b – volume: 7 start-page: 485 year: 2008 ident: 2022031210130799800_B43 article-title: Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity publication-title: Cell Metab doi: 10.1016/j.cmet.2008.04.002 – volume: 38 start-page: 737 year: 2006 ident: 2022031210130799800_B39 article-title: Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2005.08.007 – volume: 101 start-page: 8852 year: 2004 ident: 2022031210130799800_B22 article-title: Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0308096101 – volume: 41 start-page: 1798 year: 2010 ident: 2022031210130799800_B36 article-title: Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion publication-title: Stroke doi: 10.1161/STROKEAHA.110.583948 – volume: 25 start-page: 2619 year: 2011 ident: 2022031210130799800_B13 article-title: The nuclear receptor PPARβ/δ programs muscle glucose metabolism in cooperation with AMPK and MEF2 publication-title: Genes Dev doi: 10.1101/gad.178434.111 – volume: 103 start-page: 3444 year: 2006 ident: 2022031210130799800_B15 article-title: PPARdelta regulates glucose metabolism and insulin sensitivity publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0511253103 – volume: 28 start-page: 698 year: 2011 ident: 2022031210130799800_B33 article-title: Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE) publication-title: Adv Ther doi: 10.1007/s12325-011-0040-2 – volume: 4 start-page: 407 year: 2006 ident: 2022031210130799800_B14 article-title: PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes publication-title: Cell Metab doi: 10.1016/j.cmet.2006.10.003 – volume: 14 start-page: 378 year: 2011 ident: 2022031210130799800_B31 article-title: C2 domain-containing phosphoprotein CDP138 regulates GLUT4 insertion into the plasma membrane publication-title: Cell Metab doi: 10.1016/j.cmet.2011.06.015 – volume: 13 start-page: 340 year: 2007 ident: 2022031210130799800_B41 article-title: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment publication-title: Nat Med doi: 10.1038/nm1546 – volume: 17 start-page: 2299 year: 2003 ident: 2022031210130799800_B12 article-title: Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability publication-title: FASEB J doi: 10.1096/fj.03-0269fje – volume: 332 start-page: 554 year: 2010 ident: 2022031210130799800_B45 article-title: Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.109.159806 – volume: 47 start-page: 507 year: 1998 ident: 2022031210130799800_B8 article-title: PPAR-γ: adipogenic regulator and thiazolidinedione receptor publication-title: Diabetes doi: 10.2337/diabetes.47.4.507 – volume: 4 start-page: 88 year: 2012 ident: 2022031210130799800_B21 article-title: Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity publication-title: J Mol Cell Biol doi: 10.1093/jmcb/mjs001 – volume: 54 start-page: 3442 year: 2005 ident: 2022031210130799800_B6 article-title: Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity publication-title: Diabetes doi: 10.2337/diabetes.54.12.3442 – volume: 297 start-page: E1056 year: 2009 ident: 2022031210130799800_B29 article-title: Restoring AS160 phosphorylation rescues skeletal muscle insulin resistance and fatty acid oxidation while not reducing intramuscular lipids publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.90908.2008 – volume: 150 start-page: 862 year: 2009 ident: 2022031210130799800_B28 article-title: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones publication-title: Endocrinology doi: 10.1210/en.2008-0502 – volume: 2 start-page: 559 year: 1998 ident: 2022031210130799800_B19 article-title: A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance publication-title: Mol Cell doi: 10.1016/S1097-2765(00)80155-0 – volume: 50 start-page: 1192 year: 2009 ident: 2022031210130799800_B44 article-title: PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. publication-title: J Hepatol doi: 10.1016/j.jhep.2009.01.021 – volume: 8 start-page: 384 year: 2008 ident: 2022031210130799800_B32 article-title: CaMKII-mediated phosphorylation of the myosin motor Myo1c is required for insulin-stimulated GLUT4 translocation in adipocytes publication-title: Cell Metab doi: 10.1016/j.cmet.2008.09.011 – volume: 25 start-page: 275 year: 2010 ident: 2022031210130799800_B34 article-title: Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients publication-title: Nutr Hosp – volume: 461 start-page: 997 year: 2009 ident: 2022031210130799800_B26 article-title: Spatiotemporal control of cell signalling using a light-switchable protein interaction publication-title: Nature doi: 10.1038/nature08446 – volume: 13 start-page: 383 year: 2012 ident: 2022031210130799800_B30 article-title: Regulation of glucose transport by insulin: traffic control of GLUT4 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3351 – volume: 54 start-page: 1157 year: 2005 ident: 2022031210130799800_B47 article-title: Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ publication-title: Diabetes doi: 10.2337/diabetes.54.4.1157 – volume: 302 start-page: H1219 year: 2012 ident: 2022031210130799800_B2 article-title: The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00796.2011 – volume: 22 start-page: 1104 year: 2010 ident: 2022031210130799800_B23 article-title: The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK-AMPK-dependent mechanism publication-title: Cell Signal doi: 10.1016/j.cellsig.2010.03.004 – volume: 48 start-page: 51 year: 2006 ident: 2022031210130799800_B37 article-title: Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice publication-title: Hypertension doi: 10.1161/01.HYP.0000225402.69580.1d – volume: 57 start-page: 1405 year: 2008 ident: 2022031210130799800_B42 article-title: Liver-specific peroxisome proliferator-activated receptor α target gene regulation by the angiotensin type 1 receptor blocker telmisartan publication-title: Diabetes doi: 10.2337/db07-0839 – reference: 9568680 - Diabetes. 1998 Apr;47(4):507-14 – reference: 17347480 - Circ Res. 2007 Apr 13;100(7):1063-70 – reference: 22227126 - Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1219-30 – reference: 14758356 - Nat Med. 2004 Mar;10(3):245-7 – reference: 17084713 - Cell Metab. 2006 Nov;4(5):407-14 – reference: 17500064 - J Biol Chem. 2007 Jul 6;282(27):19313-20 – reference: 22241835 - J Mol Cell Biol. 2012 Apr;4(2):88-96 – reference: 16198140 - Int J Biochem Cell Biol. 2006;38(5-6):737-51 – reference: 20228403 - N Engl J Med. 2010 Apr 22;362(16):1477-90 – reference: 15328533 - PLoS Biol. 2004 Oct;2(10):e294 – reference: 19147680 - Endocrinology. 2009 Feb;150(2):862-70 – reference: 15007034 - Hypertension. 2004 May;43(5):993-1002 – reference: 12796280 - Hypertension. 2003 Jul;42(1):76-81 – reference: 21156825 - Cardiovasc Res. 2011 Apr 1;90(1):122-9 – reference: 15184668 - Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8852-7 – reference: 22135324 - Genes Dev. 2011 Dec 15;25(24):2619-30 – reference: 20206685 - Cell Signal. 2010 Jul;22(7):1104-13 – reference: 20449538 - Nutr Hosp. 2010 Mar-Apr;25(2):275-9 – reference: 18522830 - Cell Metab. 2008 Jun;7(6):485-95 – reference: 19996061 - Hypertension. 2010 Feb;55(2):523-30 – reference: 18566335 - Am J Respir Cell Mol Biol. 2008 Dec;39(6):689-96 – reference: 14525942 - FASEB J. 2003 Dec;17(15):2299-301 – reference: 17223076 - Biochem Biophys Res Commun. 2007 Mar 9;354(2):427-33 – reference: 18184928 - Diabetes. 2008 May;57(5):1405-13 – reference: 21907143 - Cell Metab. 2011 Sep 7;14(3):378-89 – reference: 16306360 - Diabetes. 2005 Dec;54(12):3442-52 – reference: 21035761 - Cell Metab. 2010 Nov 3;12(5):509-20 – reference: 22617471 - Nat Rev Mol Cell Biol. 2012 Jun;13(6):383-96 – reference: 21744143 - Adv Ther. 2011 Aug;28(8):698-706 – reference: 17322896 - Nat Med. 2007 Mar;13(3):340-7 – reference: 19805479 - Pharmacol Rev. 2009 Sep;61(3):373-93 – reference: 15793256 - Diabetes. 2005 Apr;54(4):1157-63 – reference: 19046570 - Cell Metab. 2008 Nov;8(5):384-98 – reference: 19724017 - Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1056-66 – reference: 20176998 - Hypertension. 2010 Apr;55(4):869-79 – reference: 20595663 - Stroke. 2010 Aug;41(8):1798-806 – reference: 11185637 - J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1380-90 – reference: 16717145 - Hypertension. 2006 Jul;48(1):51-7 – reference: 22442298 - Diabetes. 2012 Apr;61(4):778-9 – reference: 15048110 - Nat Med. 2004 May;10(5):481-3 – reference: 20429048 - Exp Clin Endocrinol Diabetes. 2010 Oct;118(9):657-61 – reference: 19906781 - J Pharmacol Exp Ther. 2010 Feb;332(2):554-61 – reference: 19749742 - Nature. 2009 Oct 15;461(7266):997-1001 – reference: 19398227 - J Hepatol. 2009 Jun;50(6):1192-201 – reference: 16492734 - Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3444-9 – reference: 19822796 - Hypertension. 2009 Dec;54(6):1353-9 – reference: 9844629 - Mol Cell. 1998 Nov;2(5):559-69 |
| SSID | ssj0006060 |
| Score | 2.2706478 |
| Snippet | The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We... The mechanisms of the improvement of glucose homeostasis through anglotensin receptor blockers are not fully elucidated in hypertensive patients. We... |
| SourceID | unpaywall pubmedcentral proquest gale pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 762 |
| SubjectTerms | Analysis Angiotensin II Type 1 Receptor Blockers - pharmacology Angiotensin II Type 1 Receptor Blockers - therapeutic use Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Benzimidazoles - pharmacology Benzimidazoles - therapeutic use Benzoates - pharmacology Benzoates - therapeutic use Biological and medical sciences Biological Transport - drug effects Cell Line Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - pathology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Enzyme Inhibitors - pharmacology Etiopathogenesis. Screening. Investigations. Target tissue resistance Fundamental and applied biological sciences. Psychology Glucose - metabolism Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Resistance Ligands Medical sciences Metabolism Mice Mice, Knockout Muscle, Skeletal - drug effects Muscle, Skeletal - enzymology Muscle, Skeletal - metabolism Muscle, Skeletal - pathology Phosphatidylinositol 3-Kinase - antagonists & inhibitors Phosphatidylinositol 3-Kinase - chemistry Phosphatidylinositol 3-Kinase - metabolism Physiological aspects PPAR gamma - agonists PPAR gamma - antagonists & inhibitors PPAR gamma - genetics PPAR gamma - metabolism Random Allocation Signal Transduction - drug effects Striated muscle. Tendons Telmisartan Up-Regulation - drug effects Vertebrates: osteoarticular system, musculoskeletal system |
| Title | Telmisartan Improves Insulin Resistance of Skeletal Muscle Through Peroxisome Proliferator–Activated Receptor-δ Activation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23238297 https://www.proquest.com/docview/1312172770 https://pubmed.ncbi.nlm.nih.gov/PMC3581229 https://diabetes.diabetesjournals.org/content/diabetes/62/3/762.full.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1939-327X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: KQ8 dateStart: 19980101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1939-327X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: KQ8 dateStart: 20000101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1939-327X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: DIK dateStart: 19520101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1939-327X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1939-327X dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: RPM dateStart: 20080701 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1939-327X dateEnd: 20130731 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1939-327X dateEnd: 20130731 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1939-327X dateEnd: 20130731 omitProxy: true ssIdentifier: ssj0006060 issn: 1939-327X databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLa2VgIkxP9PYVThR8BN2sZ26uSyTBsF0aoardRdRY5jj2olqZZWCCQk3oFX4Tl4CJ6Ec-qkLFAkLriJouSLEzuf7WP7-DuEPOFeHCgOFanTMcrlsYA6x8PAjZn0JDdCU477nQfDbn_CX0_96Q7pl3thyhnHVnlSFGm-XtVH921oizeodpe2WRvqcwsnq1uLxOySetcHq7xG6pPhqHdsG2KKKpzCLjCHLqNiakWGKGOincToneBjuOJzXVPRQF9eyBwKy9goF9vM0D-9KS-u0oX8-EHO5-e6qsOrZFZm0nqonLZWy7ilPv2m__g_SuEauVLYs07PEvA62dHpDXJhUKzY3ySfx3oOVAKCytSxMxg6d15ZD3jnSOdovwLxnMw4b0-hD4TBgDNY5ZCYM7YxhJyRhpzM8uy9dkYYZMjotW_Ajy9fe2odnU0nkBL652Rn7vdvTnEVGHeLTA4Pxvt9twj54Cou-NLVQohEGmpYwhSwS4A5IxkMWQ2jRsecy6AbYocKVhQPjK8CHZjExIk2fkfFnN0mtTRL9V3iAEYHvhKe8SUPkjgUVHqdxAsNk1QlcYM8L_92pAo9dAzLMY9gXITEiJAYERKjQR5toAsrArIVhJSJUFQjRa-dE7nK8yh4-SbqMeoxjIQoGuRZATIZvEzJYhMEfDLqcFWQTyvIE6tCvg24VwHCP1WV280KhTcZoAJMvZAGDfKw5HSEz6LTXaqzVR55zMPwZQLzdsdy_NfTDGw9ismLCvs3AJQtr95JZ-_W8uWouEdp2CCPN_Xk76V6759Q98klug5Tgr6Be6S2PFvpB2AsLuMm2RVTAcdg32uS-ouD4eioWbQNPwHiL3Pf |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjtMwFLWGjgRIiPejMIzMQ8AmbWM7dbKsEENBdFRBK5VV5Dj2UE1JqkkjBBIS_8Cv8B18BF_CvXVSJlAkFuyq5iStnWP72j4-l5CHwk9CLaAh9XpWeyKR0OZEFHoJV74SVhom8Lzz6LA_nIqXs2C2Q4b1WZh6xbFTf6iqtFjv6qN8G_riDarbZ13ehfbcwcXqzjK1Z8huP4CovEV2p4fjwVvXETN04ZRugznyOJMzZzLEOJfdNEF1QoDpik8NTVUHfWGpCqgs67JcbAtD_1RTniuzpfr4QS0Wp4aqg0tkXhfSKVSOO-Uq6ehPv_k__o9auEwuVvEsHTgCXiE7JrtKzo6qHftr5PPELIBKQFCVUbeCYQr6wing6WtTYPwKxKO5pW-OYQyEyQAdlQU8jE5cDiE6NlCSeZG_N3SMSYasWWsDfnz5OtDr7GwmhSehPic_8b5_o9W3wLjrZHrwbPJ06FUpHzwtpFh5RkqZKsssT7kGdkkIZxSHKavlzJpECBX2IxxQIYoSoQ10aEKb2iQ1NujpRPAbpJXlmblFKGBMGGjp20CJME0iyZTfS_3IcsV0mrTJk_ptx7ryQ8e0HIsY5kVIjBiJESMx2uT-Brp0JiBbQUiZGE01MlTtHKmyKOLw-at4wJnPMROibJPHFcjm8GNaVYcg4C-jD1cD-aiBPHIu5NuAew0gvFPduLzfoPCmAExCqBexsE3u1ZyO8V4U3WUmL4vY5z6mL5NYtpuO47_u5hDrMXy8bLB_A0Db8uaVbP5ubV-OjnuMRW3yYNNO_l6rt_8JdYecZ-s0JagN3COt1Ulp7kKwuEr2q37gJwD2cJE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Telmisartan+improves+insulin+resistance+of+skeletal+muscle+through+peroxisome+proliferator-activated+receptor-%CE%B4+activation&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Li%2C+Li&rft.au=Luo%2C+Zhidan&rft.au=Yu%2C+Hao&rft.au=Feng%2C+Xiaoli&rft.date=2013-03-01&rft.pub=American+Diabetes+Association&rft.issn=0012-1797&rft.volume=62&rft.issue=3&rft.spage=762&rft_id=info:doi/10.2337%2Fdb12-0570&rft.externalDocID=A321335197 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |